Ponatinib is indicated for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adult patients who are resistant or intolerant to other tyrosine kinase inhibitors (TKIs). The PACE trial found that ponatinib achieved high rates of response in CML and Ph+ ALL patients, including those with the T315I mutation, with durable responses. Common adverse events included rash, hypertension, and myelosuppression. Arterial thrombotic events were observed, with a median onset of 13.8 months, but the exposure-adjusted incidence did not increase over time. Responses were seen in CML and Ph+ ALL
Ik ben Saskia Vugts ( 1963 ) Al jaren schilder ik portretten in opdracht met olieverf. Na mijn opleiding aan de academie voor schone kunsten Arendonk ben ik professioneel portretschilder. Mijn grootste inspiratiebron is de unieke mens. Met liefde probeer ik in ieder portret een hart en ziel te leggen.Op een geheel eigenwijze schilder ik mijn portretten op de authentieke manier met een knipoog naar modern design. Voorheen tekende ik portretten met pastel, ik maak ook dierportretten in opdracht. Aan een Portretopdracht gaat een fotoshoot vooraf. Waar veel energie ingestoken wordt, het is belangrijk om een goed beeld van de te portretteren persoon te krijgen. Na een aantal maanden is het te vervaardigen portret klaar. Voor meer informatie kijk op mijn persoonlijke website http://saskiavugts.nl/portret-in-opdracht/
Presented at the American Society for Clinical Oncology Gastroenterology in January 2017 in San Francisco by Eric Raymond
Background: Sunitinib was approved by the FDA in 2011 for treatment of progressive, well-differentiated, advanced pancreatic neuroendocrine tumors (pNETs) based on a pivotal phase III study (NCT00428597) that showed a significant increase in progression-free survival (PFS) over placebo following early study termination. Subsequently, the FDA requested a post-approval study to support these findings.
Methods: In this open-label, phase IV clinical trial (NCT01525550), patients with progressive, well-differentiated, unresectable advanced/metastatic pNETs received continuous sunitinib 37.5 mg once daily. Eligibility criteria were similar to the phase III study. Primary endpoint was investigator-assessed PFS per RECIST 1.0. This study is ongoing.
Results: Sixty one treatment-naïve and 45 previously treated patients with progressive pNETs were treated with sunitinib: mean age, 54.6 years; males, 59.4%; white, 63.2%; ECOG PS 0, 65.1% or PS 1, 34.0%; and prior somatostatin analog, 48.1% (treatment-naïve, 39.3%; previously treated, 60.0%). At the data cutoff date, 82 (77%) patients discontinued treatment, mainly due to disease progression (46%). Median duration of treatment was ~11.9 months. Investigator-assessed median PFS (mPFS) was 13.2 months (95% CI, 10.9–16.7) in the overall population, with comparable mPFS in treatment-naïve and previously treated patients (13.2 vs 13.0 months). mPFS per independent radiologic review was 11.1 months (95% CI, 7.4–16.6). Objective response rate (ORR) per RECIST was 24.5%: 21.3% in treatment-naïve and 28.9% in previously treated patients. Median overall survival, although not yet mature, was 37.8 months. Treatment-emergent, all-causality adverse events (AEs) reported by ≥20% of all patients included neutropenia, diarrhea, leukopenia, fatigue, hand–foot syndrome, hypertension, abdominal pain, dysgeusia, and nausea. Most common grade 3/4 AEs were neutropenia (22%) and diarrhea (9%).
Conclusions: The mPFS of 13.2 months and ORR of 24.5% observed in this study support the outcomes of the pivotal phase III study of sunitinib in pNETs and confirm its activity in this setting. AEs were consistent with known safety profile of sunitinib.
Evaluation of POSSUM scoring system in patients with perforation peritonitis ...Kundan Singh
Background: Continuous audit of clinical practice is an essential part of making improvements in medicine and
enhancing patient care. Recently, physiological and operative severity score for the enumeration of mortality and
morbidity (POSSUM) scores has been developed, which would help to identify those patients who are at increased
risk of developing complications and deaths. This scoring system is based on 12 physiological characteristics of
patient and 6 characteristics of the surgery performed.
Methods: This study was done in Department of surgery at Patna medical college, Patna, Bihar, India from April
2014 to October 2015 on 100 patients. Physiological variables were collected prior to induction of anesthesia and
operative variable collected during operation chi-square test was used for expected and actual mortality differences.
Results: In present study 100 patients of peritonitis due to different cause of intestinal perforation were studied.
Comparison of observed and POSSUM predicted mortality and morbidity rates were done. Observed to expect
mortality and morbidity ratio was 1.005 and 1.001 respectively and there was no statistically significant difference
between the predicted and observed values.
Conclusions: This study confirms and validates the findings of previous work that POSSUM is an accurate and
reliable tool for estimating in-hospital mortality.
Immunotherapy for Metastatic Triple Negative Breast Cancerbkling
Sylvia Adams, MD, medical oncologist, and associate professor at the NYU School of Medicine, discusses the latest research including the role of immunology in the treatment of triple negative metastatic breast cancer. This webinar was hosted on October 19, 2016.
Arjun Balar, MD, and Petros Grivas, MD, PhD, prepared useful practice aids pertaining to bladder cancer management for this CME activity titled "Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning the Race and Optimizing Patient Outcomes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2GpacAq. CME credit will be available until December 30, 2019.
Similar to Breccia M. Efficacia e Tollerabilità di Ponatinib. ASMaD 2015 (20)
SANDRI G. La Nutrizione Clinica al S.Eugenio. ASMaD 2017Gianfranco Tammaro
DOTT. GIANCARLO SANDRI - Convegno "Il Presente ed il Futuro della Nutrizione Clinica" - 24/03/2017 - Sala Rita Levi Montalcini - Ospedale S.Eugenio - ROMA
Sito ASMaD: http://www.asmad.net
Canale Youtube: https://youtu.be/O7NcSQjnRR4
GASBARRINI A. Nutrizione Clinica e Gastroenterologia. ASMaD 2017Gianfranco Tammaro
PROF. ANTONIO GASBARRINI - Convegno "Il Presente ed il Futuro della Nutrizione Clinica" - 24/03/2017 - Sala Rita Levi Montalcini - Ospedale S.Eugenio - ROMA
Sito ASMaD: http://www.asmad.net
Canale Youtube: https://youtu.be/FYlsQzE8xfk
PALLAGROSI R. Gli Alimenti a fini medici speciali: nuova definizione e normat...Gianfranco Tammaro
DOTT.SSA ROBERTA PALLAGROSI - Convegno "Il Presente ed il Futuro della Nutrizione Clinica" - 24/03/2017 - Sala Rita Levi Montalcini - Ospedale S.Eugenio - ROMA
Sito ASMaD: http://www.asmad.net
Canale Youtube: https://youtu.be/86dXMRSe6hQ
DE SANTIS D. Il Supporto Nutrizionale in Ospedale: ieri, oggi, domani. ASMaD ...Gianfranco Tammaro
CPSI DANIELA DE SANTIS - Convegno "Il Presente ed il Futuro della Nutrizione Clinica" - 24/03/2017 - Sala Rita Levi Montalcini - Ospedale S.Eugenio - ROMA
Sito ASMaD: http://www.asmad.net
Canale Youtube: https://youtu.be/VhUPt78wU4Y
Giorgetti G.M. Il Supporto Nutrizionale in Ospedale: ieri, oggi, domani. ASMa...Gianfranco Tammaro
DOTT. GIAN MARCO GIORGETTI - Convegno "Il Presente ed il Futuro della Nutrizione Clinica" - 24/03/2017 - Sala Rita Levi Montalcini - Ospedale S.Eugenio - ROMA
Sito ASMaD: http://www.asmad.net
Canale Youtube: https://youtu.be/hDOnIcyTagc
Franceschi F. Il Ruolo del Gastroenterologo nel DEA. ASMaD 2016Gianfranco Tammaro
PROF. FRANCESCO FRANCESCHI - 3° Giornata Master ECM in Gastroenterologia 2016 (25/11/2016) - Fondazione Santa Lucia - Sala Congressi - Roma
Sito: www.asmad.net
Canale Youtube: https://youtu.be/NZzctPkJiGI
Gasbarrini A. Microbiota, Antibiotici e Probiotici in Gastroenterologia. ASMa...Gianfranco Tammaro
PROF. ANTONIO GASBARRINI - 3° Giornata Master ECM in Gastroenterologia 2016 (25/11/2016) - Fondazione Santa Lucia - Sala Congressi - Roma
Sito: www.asmad.net
Canale Youtube: https://youtu.be/ouYcXg_ZtJM
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Breccia M. Efficacia e Tollerabilità di Ponatinib. ASMaD 2015
1. Efficacia e tollerabilità di
ponatinib
Massimo Breccia
Azienda Policlinico Umberto I°
Sapienza Università
Roma
2. Indicazioni, posologia e raccomandazioni
Iclusig è indicato in pazienti adulti affetti da:
- LMC in fase cronica, accelerata o blastica resistenti o intolleranti a
dasatinib o nilotinib e per i quali il successivo trattamento con imatinib
non è clinicamente appropriato, oppure in pazienti nei quali è stata
identificata la T315I
- LLA Ph+ resistenti e intolleranti a dasatinib e per i quali il successivo
trattamento con imatinib non è clinicamente appropriato, oppure in
pazienti nei quali è stata identificata la T315I
La dose raccomandata inizialmente è 45 mg una volta al giorno
Prima di iniziare il trattamento si deve valutare il profilo
cardiovascolare del paziente e i fattori di rischio cardiovascolare
devono essere gestiti attivamente.
7. Profilo di tollerabilità studio di fase 1
Molti degli eventi avversi registrati erano di entità moderata
I più frequenti SAEs registrati sono stati: dolori addominali, ipertensione,
incremento di lipasi, fibrillazione atriale, infarto miocardico e pancreatite
Molti degli eventi avversi sono avvenuti nel primo anno di terapia.
Tempo mediano di insorgenza di ATEs: 13.8 mesi
Tempo mediano di insorgenza VTEs: 18.4 mesi
4 pts hanno sospeso per ATE, 1 pt per VTE. No decessi
Talpaz et al, ASH 2014 abst 4558
9. Methods
• The PACE trial design has previously been described.1
The primary endpoints were MCyR by 12
months for CP-CML and MaHR by 6 months for AP-CML, BP-CML, and Ph+ ALL. Secondary
endpoints included major molecular response (MMR), time to and duration of response,
progression-free survival (PFS), overall survival (OS), and safety
• Response assessments were conducted every 3 months for CP-CML patients
• While 45 mg QD was the starting ponatinib dose, dose reductions to 30 mg QD or 15 mg QD
were allowed to manage AEs
• In October 2013, a partial clinical hold was placed on new patient enrollment in ARIAD-sponsored
ponatinib trials following an accumulation of ATEs with longer-term follow-up2
• Unless benefit–risk analysis justified treatment with a higher dose, the following dose reductions
were recommended in October 2013 for ongoing PACE patients:
– 15 mg/day for CP-CML with MCyR
– 30 mg/day for CP-CML without MCyR
– 30 mg/day for advanced-phase CML
• Exposure-adjusted AE rates were calculated as: [Number of patients with first event in the
specified interval/total exposure for the interval (person years)] × 100
1. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias. N Engl J Med. 2013;369:1783-
1796.
2. ARIAD announces changes in the clinical development program of Iclusig [press release]. Cambridge, MA: ARIAD Pharmaceuticals, Inc.; October 9,
2013.
10. Baseline Characteristics and Patient
Disposition
Totala,b
N=449
CP-CML
n=270
Median age (range), y 59 (18–94) 60 (18–94)
Median time since diagnosis (range), y 6 (0.3–28) 7 (0.5–27)
Prior TKI therapy,c
n (%)
≥2 TKIs 418 (93) 252 (93)
≥3 TKIs 262 (58) 161 (60)
Median duration of treatment (range), mo 16.7 (0.03–48.5) 32.1 (0.1–48.5)
Median follow-up (range), mo 34.2 (0.1–48.6) 38.4 (0.1–48.6)
Ongoing, n (%) 150 (33) 121 (45)
Discontinued treatment, n (%) 299 (67) 149 (55)
Progressive disease 96 (21) 25 (9)
AE 66 (15) 46 (17)
Deathd
24 (5) 8 (3)
Othere
113 (25) 70 (26)
a
Includes 5 patients (3 CP-CML, 2 AP-CML) who were non–cohort assigned (post-imatinib, non-T315I), but treated; 4 of 5 remain on study; b
44% of
patients had no mutation (51% CP-CML), and 26% had mutations other than T315I (25% CP-CML) at study entry; c
Includes approved and investigational
TKIs; d
7 deaths were assessed by investigators as possibly or probably related to ponatinib (CP-CML: pneumonia, acute myocardial infarction; AP-CML:
fungal pneumonia, gastrointestinal hemorrhage; BP-CML/Ph+ ALL: cardiac arrest, gastric hemorrhage, mesenteric arterial occlusion); e
Includes
withdrawal by subject (including for transplant), lack of efficacy, investigator decision, loss to follow-up, noncompliance, protocol violation, and other
reasons
Data as of 06 October 2014
11. Efficacy of Ponatinib in CP-CML
• 39% of CP-CML patients achieved MMR or better
– Median times to MCyR, CCyR, and MMR for responders were 2.8 (1.6–24.5) months, 2.8 (1.6–35.7)
months, and 5.5 (1.8–32.9) months, respectively
• Responses were durable, with an estimated 83% of patients remaining in MCyR at 36 months
MR4, 4-log molecular response, ≤0.01% BCR-ABLIS
; MR4.5, 4.5-log molecular response, ≤0.0032% BCR-ABLIS
Responses at Any Time Duration of Response
Data as of 06 October 2014
12. Progression-Free Survival and Overall
Survival in CP-CML
a
Progression from CP was defined as death, development of AP or BP, loss of complete hematologic response (in absence of cytogenetic response), loss of
MCyR, or increasing white blood cell count without complete hematologic response
Data as of 06 October 2014
13. Overall Survival in AP-CML, BP-CML, and Ph+ ALL
a
Includes myeloid BP (n=52) and lymphoid BP (n=10) Data as of 06 October 2014
14. Denominator only includes patients who were evaluable at the landmark time point
Patients Achieving Landmark Responses
PatientsAchieving
LandmarkResponse(%)
209 203 175 225 230 191 188 161 207 211 141 137 121 158 162
15. PFS and OS by 3-Month
BCR-ABL ≤1% vs >1%
Two-year PFS and OS based on Kaplan-Meier estimates and calculated from landmark time point (3 months)
Progression defined as death, development of AP or BP, loss of CHR (in absence of cytogenetic response), loss of MCyR, or increasing WBC without CHR
75 68 54 25
133 90 61 27
No. at risk
77 71 65 27
148 128 110 55
2y PFS=87%
2y PFS=62%
2y OS=90%
P=0.0357
2y OS=84%
P=0.0003
2 Years 2 Years
PFS OS
16. PFS and OS by 3-Month
MMR vs No MMR
Two-year PFS and OS based on Kaplan-Meier estimates and calculated from landmark time point (3 months)
32 28 23 11
180 134 95 42
33 30 28 12
197 173 150 71
2y PFS=97%
2y PFS=67%
2y OS=97%
2y OS=84%
P=0.0324P=0.0006
2 Years 2 Years
PFS OS
No. at risk
18. Profilo di tollerabilità studio PACE
I più frequenti AEs registrati sono stati: rash e cute secca, sintomi
costituzionali (costipazione, cefalea, fatigue, febbre, nausea, vomito e
diarrea), ipertensione, incremento lipasi, mielosoppressione
(piastrinopenia, neutropenia e anemia)
I più frequenti SAEs (grado 3/4): piastrinopenia, neutropenia, anemia,
incremento lipasi, ipertensione.
Cortes et al, ASH 2014 abst 3135
19. Eventi CV studio PACE
Tempo mediano
di insorgenza di
ATEs in CP:
13.8 mesi
Tempo mediano
di insorgenza
VTEs in CP:
21 mesi
Cortes et al, ASH 2014 abst 3135
20. Exposure-adjusted yearly incidence rate per
studio PACE
Cortes et al, ASH 2014 abst 3135
• Non c’è incremento nell’incidenza di nuovi eventi trombotici arteriosi e venosi con
l’aumentare del tempo di esposizione
21. Rischio di eventi trombotici arteriosi per categoria
Cortes et al, ASH 2014 abst 3135
Sono da considerare
come fattori di rischio per
ATE:
• Età > 65
• Sesso M
• Diabete
• Precedente ischemia
cardiaca
• Ipertensione
• Ipercolesterolemia
• Avere più di 3 fattori di
rischio concomitanti
22. Occorrenza di ATEs in accordo alla
riduzione di dose (studio PACE)
Cortes et al, ASH 2014 abst 3135
5/70 (7%) pazienti senza precedenti ATEs hanno avuto un nuovo evento trombotico
arterioso dopo una riduzione prospettica del dosaggio
7/67 (10%) pazienti che hanno mantenuto la dose e non avevano avuto un precedente
evento trombotico arterioso hanno avuto un nuovo evento
24. Baseline Characteristics of Patients With T315I
CP-CML
(n=76)
AP-CML
(n=19)
BP-CML
(n=26)
Ph+ ALL
(n=26)
Total
(N=147)
Median age, years (range) 50 (18–87) 52 (24–78) 47 (18–74) 62 (23–80) 52 (18–87)
Median time since diagnosis,a
years (range) 4.6 (0.8–19) 6.3 (1.1–16) 2.3 (0.5–14) 1.3 (0.5–7) 3.6 (0.5–19)
Median follow-up, months (range) 36 (1.5–70) 21 (3.1–45) 2.9 (0.4–9) 2.7 (0.1–40) 8.9 (0.1–70)
Median dose intensity, mg/day (range) 34 (4.9–56) 38 (7.3–45) 44 (8.0–47) 45 (1.7–60) 39 (1.7–60)
Stem cell transplant, n (%) 1 (1) 2 (11) 6 (23) 5 (19) 14 (10)
Prior TKI therapy, n (%)
1 TKI 11 (14) 3 (16) 1 (4) 7 (27) 22 (15)
2 TKIs 35 (46) 6 (32) 13 (50) 12 (46) 66 (45)
≥3 TKIs 30 (39) 10 (53) 12 (46) 7 (27) 59 (40)
Data as of 26 September 2014 (Phase 1) and 6 October 2014
a
Time from initial diagnosis to first dose date; AP, accelerated phase; BP, blast phase
> The analysis included 147 patients with a baseline T315I mutation from the phase 1 (n=19)
and PACE (n=128) trials, with a median follow-up of 3 years for CP-CML patients
> Overall, PACE patients with T315I at baseline were younger, less heavily treated, and had a
shorter time since diagnosis, compared with the overall PACE population1,2
1. Cortes JE, et al. N Engl J Med. 2013;369:1783-1796. 2. Cortes JE, et al. ASH 2014 (abstract 3135).
25. Response at Any Time in Patients with T315I
n (%)
CP-CML
(n=76)
AP-CML
(n=19)
BP-CML
(n=26)
Ph+ ALL
(n=26)
MaHR NA 11 (58) 7 (27) 10 (38)
MCyR 57 (75) 12 (63) 8 (31) 10 (38)
CCyR 55 (72) 8 (42) 5 (19) 8 (31)
MMR 46 (61) 7 (37) 1 (4) 2 (8)
MR4 34 (45) 0 0 1 (4)
MR4.5 28 (37) 0 0 0
CCyR, complete cytogenetic response; MaHR, major hematologic response; MCyR, major cytogenetic response; MMR, major molecular response; MR4, 4-log
molecular response, ≤0.01% BCR-ABLIS
; MR4.5, 4.5-log molecular response, ≤0.0032% BCR-ABLIS
; NA, not applicable
In the phase 1 trial, CP-CML patients with T315I (n=12) had the following responses, n (%): MCyR, 11 (92); CCyR, 10 (83); MMR, 9 (75); MR4, 8 (67); MR4.5, 6 (50)
In the PACE trial, CP-CML patients with T315I (n=64) had the following responses, n (%): MCyR, 46 (72); CCyR, 45 (70); MMR, 37 (58); MR4, 26 (41); MR4.5, 22 (34)
Data as of 26 September 2014 (Phase 1) and 6 October 2014
26. Duration of MCyR and CCyR in CP-CML Patients With T315I
a
Loss of response is defined as a single time point at which the criteria for response are not met
> Majority of CP-CML patients with the T315I mutation at baseline maintained response
- 83% of patients were estimated to remain in MCyR at 3 years
- 81% of patients were estimated to remain in CCyR at 3 years
> Median duration of response not reached
Data as of 26 September 2014 (Phase 1) and 6 October 2014
27. Progression-Freea
and Overall Survival in Patients With
T315I Mutation in the PACE Trial
a
Progression from CP was defined as death, development of AP or BP, loss of complete hematologic response (in absence of cytogenetic response), loss of
MCyR, or increasing white blood cell count without complete hematologic response
> In the phase 1 trial (OS and PFS not collected), 11/12 CP-CML patients are alive and
ongoing; 1 patient discontinued because of disease progression
Data as of 26 September 2014 (Phase 1) and 6 October 2014
36-mo PFS: 59%
36-mo PFS: 40%
Median: 31.5 mo
36-mo PFS: 0% (BP-CML)
Median: 4.1 mo
36-mo PFS: 0% (Ph+ ALL)
Median: 2.6 mo
36-mo OS: 78%
36-mo OS: 63%
36-mo OS: 0% (BP-CML)
Median: 6.9 mo
36-mo OS: 7% (Ph+ ALL)
Median: 6.5 mo
35. • Fino ad oggi sono noti pochi effetti diretti di ponatinib sulle cellule
vascolari, ma preliminari osservazioni (P. Valent et al) sono state
fornite di effetto sulla crescita e sopravvivenza, al pari di nilotinib.
• Sono in corso studi di valutazione su eventuali target molecolari
responsabili di effetti “off-target”: VEGF, KDR (target di ponatinib) e
TEK/Tie-2.
• Per nilotinib al contrario sono stati evidenziati: meccanismi
metabolici (iperglicemia, ipercolesterolemia), effetti diretti pro-
aterogenici (up-regolazione molecole di adesione sulle cellule
endoteliali e vasospasmo), effetti anti-angiogenici (effetto inibitorio
diretto sulla crescita delle cellule endoteliali con conseguente
ridotta ricanalizzazione), funzioni piastriniche alterate, riduzione
mast-cells.
Meccanismi potenziali per eventi CV
Valent et al, Blood 2014
36. • Attività in vitro di ponatinib e altri TKIs su colture cellulari (Ba/F3),
ASMC (aortic smooth muscle cells), HUVEC (umbilical vein), HAEC
(aortic), HPAEC (pulmonary artery endothelial cells).
• Ponatinib inibisce in vitro l’attività di kinasi multiple con IC50s entro
10-fold di ABL, incluso VEGFR, PDGFR, FGFR, EPH receptor e SRC
kinases, KIT, RET, TIE2, e FLT3.
• Per le cellule derivate da colture vascolari, ponatinib inibisce la
viabilità e la crescita di HUVEC con IC50 di 261 nM, mentre gli altri
TKIs hanno un IC50s >2000 nM. Effetti modesti di ponatinib su
HAECs, HPAECs e ASMCs (rispettivamente, IC50s 1533, 490 e 750
nM).
• Ponatinib (IC50 20 nM) e altri inibitori di VEGFR2 inibiscono
potentemente la sopravvivenza e la crescita di HUVECs.
Comparative TKI Profiling Analyses to Explore Potential
Mechanisms of Ponatinib-Associated Arterial Thrombotic Events
Rivera et al, ASH 2014; abstr 1783
37. Iclusig non dovrebbe essere utilizzato in pazienti con storia
pregressa di infarto miocardico, precedente rivascolarizzazione o
stroke, bilanciando rischi-benefici del trattamento. In questi pazienti
dovrebbero essere considerate strategie terapeutiche opzionali.
Un monitoraggio continuo per occlusioni vascolari e possibile
tromboembolismo dovrebbe essere eseguito e il farmaco
interrotto immediatamente in caso di occlusione. Considerare poi i
rischi/benefici per riprendere successivamente la terapia.
L’ipertensione può contribuire al rischio di eventi arteriosi
trombotici. Durante il trattamento con Iclusig è importante
monitorizzare la pressione arteriosa e correggerla ad ogni visita
di controllo. Iclusig dovrebbe essere temporaneamente interrotto se
la pressione arteriosa non è controllata.
Raccomandazioni (II)
Iclusig SmPC Sep 2014
38. Impact of Dose Intensity of Ponatinib on Selected Adverse
Events: Multivariate Analyses from a Pooled Population of
Clinical Trial Patients
• Univariate and multivariate logistic regression analyses were conducted
for each outcome (presence/absence of treatment-emergent AEs) and
dose intensity measure (average daily dose through day of event) in 671
patients with all baseline covariates (diabete, storia di eventi CV, età, etc).
• Dall’analisi risulta che, aggiustando per i fattori predisponenti, alcuni
eventi avversi (pancreatite, rash ed eventi CV) risultano fortemente
correlati alla dose intensity.
Knickerbocker et al ASH 2014; abstr 4546
39. Conclusioni
• Dagli studi presentati conferma dell’efficacia
di ponatinib in varie fasi di malattia
• Dosaggio raccomandato attuale ancora 45 mg
• Seguire raccomandazioni come da scheda
tecnica